VialFacts DeutschSvenska

Claims on this page checked 2026-08-24

Emideltide (DSIP)

In a six-person double-blind crossover, DSIP raised median total sleep by 59% during 130 minutes versus placebo (PMID 6895513; checked 24 Aug 2026). PubMed lists no grant. The full-paper funder was not checked. The authors reported no mental, body, or lab side effects (PMID 6895513; checked 24 Aug 2026). A later 16-person study found weak measured effects and no likely major benefit (PMID 1299794; checked 24 Aug 2026).

What substance and sequence does DSIP identify?

The American FDA/NCATS GSRS displays Emideltide as the INN (GSRS; checked 24 Aug 2026). It lists DSIP and delta sleep-inducing peptide as names. Its nine-part sequence is WAGGDASGE.

GSRS assigns UNII YN28Z5YZ73 (checked 24 Aug 2026). It assigns primary CAS 62568-57-4 (same source and date). It also lists CAS 69431-45-4 as NO STRUCTURE GIVEN. The old PubMed records use that second number.

What did the first controlled human sleep study find?

DesignMeasured findingPrimary sourceFunder statusChecked
6 healthy volunteers; double-blind crossoverMedian total sleep rose 59% in 130 minutes versus placeboPMID 6895513PubMed has no grant list; full paper not verified24 Aug 2026
Same study; later night sleepShorter sleep onset, less stage 1 sleep, better sleep efficiencyPMID 6895513Same status24 Aug 2026
Same study; observed safetyWell tolerated; no psychological, physiological, or biochemical side effects reportedPMID 6895513Same status24 Aug 2026

The study found no classic drug sedation.

What did later human studies measure?

StudyResultPrimary sourceFunder statusChecked
16 chronic insomnia patients; double-blind matched pairsHigher sleep efficiency and shorter latency versus placebo; effects weak and partly possibly due to placebo changePMID 1299794PubMed has no grant list; full paper not verified24 Aug 2026
Same 16-patient studyNo change in other measures, including subjective sleep quality; authors concluded no likely major benefitPMID 1299794Same status24 Aug 2026
11 healthy men; randomized double-blind crossoverACTH-like immunoreactivity fell for at least 3 hours; plasma cortisol was unchangedPMID 2554357PubMed says non-US government support; agency not named24 Aug 2026
Same 11-man studyNo difference in urinary cortisol or monoamine metabolitesPMID 2554357Same status24 Aug 2026
24 women under isoflurane anesthesia; randomizedHeart rate rose, heart-rate variability fell, delta rhythm and burst suppression fell, BIS rose at one tested levelPMID 19142086PubMed has no grant list; full paper not verified24 Aug 2026
Same anesthesia studyEEG symmetry changed; authors concluded anesthesia depth was lightenedPMID 19142086Same status24 Aug 2026

What safety findings were reported?

The six-person study reported good tolerance and no mental, body, or lab side effects (PMID 6895513; checked 24 Aug 2026).

The 2009 anesthesia study found a faster pulse, lower HRV, and changed EEG results (PMID 19142086; checked 24 Aug 2026). Its abstract has no full harm table. The 16-person and 11-man abstracts also have none.

What does evidence tier B mean here?

Controlled human studies exist. The entry assigns tier B (checked 24 Aug 2026). The studies were small and tested different things. The tier does not set EU status.

What is the recorded EU status?

The European Commission active-substance index has no entry for Emideltide, DSIP, or delta sleep-inducing peptide (Union Register index; checked 24 Aug 2026).

The index covers central EU approvals. It does not settle national lists. The EU field remains unclear.

When was DSIP first observed in a product?

No vial test or market record is linked here (checked 24 Aug 2026). A paper or trial date is not a vial date. The first_observed field stays blank instead of using a guess.

What does this register entry cover?

This entry covers the INN, DSIP, and its sequence. It has no test result for a vial. No full guide is installed yet.

What can be in a vialAll register entries